OMER
HealthcareOmeros Corporation · Biotechnology · $830M
What is Omeros Corporation?
Omeros Corporation is a Seattle-based commercial-stage biopharmaceutical company focused on rare and serious diseases. Its pipeline targets complement-mediated disorders, immune-related cancers, and addictive conditions through small-molecule and protein therapeutics.
Omeros discovers and develops therapies for orphan indications and underserved conditions. Its lead program, narsoplimab, targets the complement system — a branch of the immune response implicated in rare blood and kidney diseases. The company generates revenue through commercialization efforts while advancing a pipeline spanning Phase I through pivotal-stage clinical trials. Additional programs address addiction, compulsive disorders, and movement conditions, broadening the therapeutic scope beyond its complement-focused core.
Omeros was founded in 2009 and is headquartered in Seattle, Washington.
- Narsoplimab (MASP-2 inhibitor) for rare blood and kidney diseases
- MASP-3 inhibitor program for alternative complement pathway disorders
- PPAR-gamma program targeting opioid and nicotine addiction
- PDE7 inhibitor for addiction, compulsive, and movement disorders
- CAR T-cell and adoptive T-cell therapies for immune-related cancers
Is OMER a Good Stock to Buy?
UQS Score rates OMER as Below Average overall.
The Risk pillar stands out as a relative bright spot, suggesting the company's financial structure carries less near-term distress risk than many small-cap biotech peers. The Growth pillar also earns a Good label, reflecting meaningful pipeline progression and the potential for clinical catalysts to drive revenue expansion.
Both the Quality and Moat pillars register as Weak — a meaningful drag on the composite score that reflects limited durable competitive advantages and underlying business fundamentals that trail sector peers.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does OMER pay dividends?
No — Omeros Corporation does not currently pay a dividend.
Omeros does not currently pay a dividend. This is typical for clinical-stage and early commercial biopharmaceutical companies, which generally reinvest available capital into research, clinical trials, and pipeline development rather than returning cash to shareholders. Investors in OMER are primarily seeking potential value through pipeline milestones rather than income.
When does OMER report earnings?
Omeros Corporation reports earnings on a quarterly cadence, consistent with standard US-listed equity reporting requirements.
Quarterly results for OMER tend to reflect the dual dynamics of commercial-stage revenue and ongoing clinical investment — meaning operating expenses tied to trials can weigh heavily on reported figures. Pipeline progress and regulatory updates often matter as much to investors as headline revenue in any given quarter.
For the most recent quarter's results and guidance commentary, visit Omeros Corporation's investor relations page directly.
OMER Price History
-12.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Omeros Corporation?
Based on Omeros Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
OMER Long-term Outlook
The Good Growth pillar label suggests Omeros carries meaningful upside potential tied to clinical milestones, particularly around narsoplimab and its complement-pathway programs. However, the Weak Quality and Moat pillars temper the fundamental outlook — durable revenue generation and competitive positioning remain key uncertainties. The Strong Risk label provides some reassurance that near-term financial stability is not the primary concern, but execution on regulatory and commercial fronts will be decisive.
Growth drivers
- Potential regulatory progress for narsoplimab across multiple rare disease indications
- Expansion of the complement-pathway pipeline into additional orphan conditions
- Commercialization leverage if lead programs achieve broader market access
Key risks
- Clinical trial failures or regulatory setbacks could significantly impair the pipeline's value
- Weak Moat rating signals limited pricing power and competitive differentiation at scale
- Small-cap biotech funding dynamics may pressure capital availability during extended development timelines
OMER vs Peers
Omeros operates in a competitive rare-disease and clinical-stage biotech landscape alongside several peers pursuing distinct therapeutic strategies.
Fortrea operates as a contract research organization, providing clinical development services rather than developing its own drug pipeline.
Zenas focuses on immunology-driven therapeutics with a pipeline built around global licensing partnerships rather than internal discovery.
Janux develops tumor-activated T-cell engager therapies for solid tumors, differentiating itself through a proprietary bispecific antibody platform.
Frequently Asked Questions
What does Omeros Corporation do?
Omeros is a commercial-stage biopharmaceutical company that discovers and develops therapies for rare and serious diseases. Its focus areas include complement-mediated disorders, immune-related cancers, and addictive conditions. The company's most advanced program, narsoplimab, targets the MASP-2 protein within the complement system and has completed pivotal studies in a rare blood disorder.
Does OMER pay dividends?
Omeros does not pay a dividend. Like most clinical-stage biopharmaceutical companies, it directs available capital toward research and pipeline development rather than shareholder distributions. Investors in OMER are generally focused on potential value creation through clinical and regulatory milestones rather than income.
When does OMER report earnings?
Omeros reports financial results on a quarterly basis, in line with standard US-listed company requirements. For the exact timing of upcoming earnings releases, check the investor relations section of the Omeros Corporation website, where scheduled reporting dates and webcasts are posted.
Is OMER a good stock to buy?
UQS Score rates OMER as Below Average overall. The Growth and Risk pillars carry Good and Strong labels respectively, but Weak Quality and Moat scores weigh on the composite. Whether OMER fits a portfolio depends on individual risk tolerance and investment goals — the full pillar breakdown is available to UQS Pro members.
Is OMER overvalued?
The UQS Valuation pillar for OMER carries a Good label, suggesting the current price is not considered Elevated relative to the company's fundamentals and peer group. For small-cap biotech names, valuation is closely tied to pipeline probability — a factor the full UQS analysis addresses in detail.
How does OMER compare to its competitors?
Omeros competes in the rare-disease and clinical-stage biotech space alongside companies like Fortrea Holdings, Zenas BioPharma, and Janux Therapeutics. Each pursues different therapeutic strategies and business models. UQS Pro members can view side-by-side pillar comparisons to assess how OMER's Quality, Growth, and Moat ratings stack up against peers.
What is OMER's market cap bracket?
Omeros Corporation is classified as a small-cap company. This places it in a segment of the market characterized by higher growth potential but also greater volatility and execution risk compared to large- or mega-cap peers. Small-cap biotech stocks can experience significant price swings around clinical and regulatory events.
Who founded Omeros Corporation?
Omeros Corporation was founded in 2009. Detailed founding history, including information about the company's founders, is publicly available through Omeros's official corporate materials and widely covered in biotech industry sources.
Is OMER a long-term quality indicator?
As a long-term quality indicator, OMER's UQS profile presents a mixed picture. The Good Growth and Strong Risk labels point to pipeline potential and near-term financial resilience, while Weak Quality and Moat scores suggest the company has not yet established the durable business characteristics associated with long-term compounding. Sustained clinical progress would be key to improving that profile.
What is the main competitive advantage of Omeros Corporation?
Omeros's primary differentiation lies in its focus on the complement system — a complex immune pathway implicated in multiple rare diseases — and its proprietary programs targeting MASP-2 and MASP-3. However, the UQS Moat pillar currently rates as Weak, indicating that durable competitive advantages have not yet been firmly established at the business level.
What sector does OMER belong to?
Omeros Corporation operates in the Healthcare sector, specifically within the biopharmaceutical industry. The company focuses on orphan and rare disease indications, a segment of healthcare characterized by smaller patient populations, specialized regulatory pathways, and potentially significant pricing power if therapies receive approval.
Is OMER a growth stock or value stock?
Based on its UQS pillar profile, OMER leans toward the growth category — the Growth pillar carries a Good label and the Valuation pillar is also rated Good, suggesting the market has not yet priced in an extreme premium. It is not a traditional value stock, as its fundamentals reflect an early commercial-stage company investing heavily in its pipeline.
Unlock Full OMER Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare OMER side-by-side with sector peers
- ✓See the full Quality and Moat breakdown in detail
- ✓Get the complete analyst-style view for Pro members
- ✓Track pillar changes as new earnings data arrives
Pro Analysis
OMER — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 24, 2026 | 48.6 | 25.0 | 26.0 | 48.0 | 75.3 | 100.0 | +3.7 |
| May 22, 2026 | 44.9 | 20.0 | 26.0 | 61.2 | 82.4 | 58.4 | +2.9 |
| May 7, 2026 | 42.0 | 1.4 | 26.0 | 61.2 | 80.1 | 73.0 | 0.0 |
| May 3, 2026 | 42.0 | 1.4 | 26.0 | 61.2 | 80.1 | 72.6 | -0.4 |
| Apr 27, 2026 | 42.4 | 1.4 | 26.0 | 61.2 | 80.1 | 75.7 | -0.4 |
| Apr 26, 2026 | 42.8 | 1.4 | 26.0 | 60.9 | 80.1 | 78.4 | 0.0 |
| Apr 22, 2026 | 42.8 | 1.4 | 26.0 | 60.7 | 80.1 | 78.6 | -3.0 |
| Apr 19, 2026 | 45.8 | 1.4 | 26.0 | 75.9 | 80.1 | 78.6 | +0.1 |
| Apr 14, 2026 | 45.7 | 1.4 | 26.0 | 70.5 | 80.1 | 84.8 | 0.0 |
| Apr 12, 2026 | 45.7 | 1.4 | 26.0 | 70.9 | 80.1 | 84.2 | 0.0 |
OMER — Pillar Breakdown
Quality
— 25.0/100 (25%)Omeros Corporation currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 48.0/100 (20%)Omeros Corporation shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Analyst consensus for future revenue growth.
Risk
— 75.3/100 (15%)Omeros Corporation carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Omeros Corporation appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
Moat
— 26/100 (25%)Omeros Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OMER.
Score Composition
Financial Data
More Stock Analysis
How is the OMER UQS Score Calculated?
The UQS (Unified Quality Score) for Omeros Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Omeros Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Omeros Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.